Quantum BioPharma Ltd C.QNTM

Bokhari, and what was he did.

[Chuckie18]

Dr. Bokhari was the Chief Executive Officer, but was awarded excessive bonuses and paying substantial costs to the corporation. The bonuses were given on February 23, 2020 and August 20, 2020, at Dr. Bokharire for $1.3, $2.5 and $2.5 million respectively in class B shares. In 2020 Dr. Bokhari's private and managed sector got reimbursement of more than $1.4 million for spending on the company with minimal divulgation and/or explanations.

[Chuckie18]

A great number of class B shares have been released from the Company, accounting for over 83% of class B shares which came out on the date of the request on 4 January 2021. He did so at a time when the stock price was equal to its present lower prices, even when there were no new cash reserves. This further weakened the appetite of shareholders and depressed share prices.

[Chuckie18]

Over this time span, Durkacz and Saeed made separate demands for access to minute books and the Company's related governance records when they concerned the appearance of governance shortcomings. The Company had not provided this information. Dr Bokhariclaimed they were non-existent but may, if inquired about the oaths of the records, make them accessible during a 24 hour cross examination.

[Chuckie18]

Mr Durkacz and Mr Saeed stated that the Commission should be able to meet and negotiate a strategy transaction at once, and once again pursued its powers, as Board members, to convene a Board meeting - this time on 30 December 2020. In view of the dire circumstances the Company faced ("Board meeting 30 December"). In a letter from the lawyers in the FSD, again, Mr Durkacz and Mr Saeed

[Chuckie18]

On 16 December 2020, Mr. Durkacz and Mr. Saeed sent an email to the members of the Board requesting a dialogue on the strategic arrangement. Larry Kaiser, an elected member of the Boards of Directors, requested a Board meeting and recommended that Dr Bokharire schedule a call by 18 December 2020. Dr. Bokharic canceled the Management Board on 18 December 2020 without any explanation.

[Chuckie18]

Although the relative value of a strategic opportunity, which between management and the board may easily be discussed and resolved, could well have been clearly contested. The Directors concerned were soon disturbed by the management of the FSD and Dr. Bokhari (other than Mr. Durkacz and Mr. Saeed). Their issues have grown over the course of time.

[Chuckie18]

Dr. Bokhari and the Board did not fulfill one such objective. •While only one of the "planted" 352 patients has been involved in a Phase 2 clinical trial approved in September 2020. •While the company declared its Cobourg Property for sale in the first quarter of 2020, the property does not seem to be able to be dispose of. • Management did not identify viable or appropriate competitive

[Chuckie18]

In 2020, the FSD charged more than $1.4 million for private and regulated companies of Dr. Bokhari with no oversight or clearing

[Chuckie18]

Bonus of $5.7 million In February2021 payment for services not yet provided equal to a million dollars for shares and/or asset of about twice the previous year's payout, was made by Stephen Buyer, Robert Ciaruffol, James Datin, GeraldGoldberg and Larry Kaiser for services not yet delivered.

[Chuckie18]

The interest of the shareholders was substantially diminished by emitting close to 16 million Class B shares, which rose 83% in just seven weeks.